A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Troglitazone has been studied across 22 research domains including 🔥 Metabolic, 🧬 Hormones, 🫁 Liver & Detox, 🔬 Oncology, 🔬 Inflammation. The primary research focus is 🔥 Metabolic with 69% of studies addressing this area.
The following compounds share molecular targets with Troglitazone, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Troglitazone is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.